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Abstract
Background
PROUD participants were randomly assigned to receive pre-exposure prophylaxis (PrEP)
immediately or after a deferred period of one-year. We report on the acceptability of this
open-label wait-listed trial design.
Methods
Participants completed an acceptability questionnaire, which included categorical study
acceptability data and free-text data on most and least liked aspects of the study. We also
conducted in-depth interviews (IDI) with a purposely selected sub-sample of participants.
Results
Acceptability questionnaires were completed by 76% (415/544) of participants. After control-
ling for age, immediate-group participants were almost twice as likely as deferred-group
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participants to complete the questionnaire (AOR:1.86;95%CI:1.24,2.81). In quantitative
data, the majority of participants in both groups found the wait-listed design acceptable
when measured by satisfaction of joining the study, intention to remain in the study, and
interest in joining a subsequent study. However, three-quarters thought that the chance of
being in the deferred-group might put other volunteers off joining the study. In free-text
responses, data collection tools were the most frequently reported least liked aspect of the
study. A fifth of deferred participants reported ‘being deferred’ as the thing they least liked
about the study. However, more deferred participants disliked the data collection tools than
the fact that they had to wait a year to access PrEP. Participants in the IDIs had a good
understanding of the rationale for the open-label wait-listed study design. Most accepted the
design but acknowledged they were, or would have been, disappointed to be randomised to
the deferred group. Five of the 25 participants interviewed reported some objection to the
wait-listed design.
Conclusion
The quantitative and qualitative findings suggest that in an environment where PrEP was
not available, the rationale for the wait-listed trial design was well understood and generally
acceptable to most participants in this study.
Introduction
Randomised placebo-controlled trials are considered the ‘gold standard’ when evaluating an
investigational product for prevention. Randomised placebo-controlled trials have provided a
breakthrough in HIV prevention by demonstrating the benefit of oral and topical pre-expo-
sure prophylaxis (PrEP) [1–7]. However, results of a few placebo-controlled trials have been
hindered by low levels of adherence. This has resulted in trial results either underestimating
the level of protection offered by PrEP [1], or showing no benefit despite evaluating efficacious
products [8–10]. Poor adherence in placebo-controlled trials initially undermined confidence
in oral products for women and has potentially jeopardised the development of a topical prod-
uct considered biologically efficacious against both HIV and herpes simplex virus [4, 11].
Measuring product acceptability has been central to PrEP trials, given participants are
unlikely to use a product they consider unacceptable [12]. However, it is important to distin-
guish between product acceptability and product adherence, as it does not necessarily follow
that participants are more likely to use a product they consider acceptable [13]. The Necessity-
Concerns-Framework (NCF) predicts adherence by measuring an individual’s belief about the
necessity of taking medication balanced against their concerns about taking it [14, 15]. This
balance of necessity and concern is skewed against adherence in placebo-controlled trials
where there is no benefit of taking a placebo, unclear benefit of taking the investigational prod-
uct, and a heightened focus on potential side effects [16]. Certainly, higher risk participants
have been more adherent in open label extension phases of trials than during the placebo-con-
trolled phase [17, 18].
Although randomised placebo-controlled trials are the ‘gold standard’, when there is strong
evidence of efficacy, there is growing interest in trial designs that promote instead of hinder
adherence [19]. One alternative is the randomised wait-listed control trial design whereby par-
ticipants either receive the intervention immediately or after a deferred period. Wait-listed
trial designs have been used extensively in health research, for example in the field of mental
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health [20], cognitive function [21], nutrition [22], pain management [23] and organ trans-
plantation [24]. However, open-label wait-listed trial designs have rarely been used in biomed-
ical HIV prevention trials [25].
In 2011, a PrEP e-group, which included community members, healthcare providers,
policy-makers and researchers, identified the need to understand the potential public-health
benefit and cost effectiveness of PrEP for the National Health Service in England [26]. They
agreed that a randomised controlled trial (RCT) was necessary but that a placebo-controlled
trial would not be able to measure the net-effect of PrEP, taking account of efficacy, adherence,
and any change in sexual behaviour as a result of using PrEP. Consequently, the PROUD
study was designed as a randomised open-label wait-listed trial. However, given PrEP was
approved for use in the United States of America, there were questions about whether the
deferred start would be acceptable to participants. In this paper, we present findings from
quantitative and qualitative data on the acceptability of the wait-listed trial design in the con-
text of the acceptability of other study procedures in the PROUD study [27, 28].
Methods
PROUD was a pragmatic open-label wait-listed RCT designed to evaluate the effectiveness
of daily oral Truvada (tenofovir disoproxil fumarate and emtricitabine) as HIV pre-exposure
prophylaxis (PrEP). The study was only called PROUD, although this was originally derived
from the longer title of: PRe-exposure Option for reducing HIV in the UK: an open-label
randomisation to immediate or Deferred daily Truvada for HIV negative gay men. PROUD
was designed as a pilot study to assess the acceptability of the study design and procedures in
advance of a larger scale clinical trial. However, due to higher than anticipated HIV incidence
and effectiveness of PrEP, the clinical trial objectives were met during the pilot [29].
Recruitment took place from November 2012 to April 2014 at 13 sexual health clinics in
England, eight in London and five outside of London. The study was advertised at the partici-
pating sexual health clinics, during community outreach activities, online and via sexual net-
working applications. Eligibility criteria included being gay or a man having sex with men,
being a trans women having sex with men, and being assigned a male gender at birth. Eligible
participants also had to be HIV negative, aged 18 or above, to have reported condomless anal
sex in the last 90 days and expected to have it again in the next 90 days, and to have previously
attended the enrolling clinic. Before enrolment, the study was explained using the participant
information sheet (PIS) and participants provided written informed consent. The UK Com-
munity Advisory Board (http://www.ukcab.net/) reviewed the protocol, which included rec-
ommended changes to the eligibility criteria which supported recruitment, and substantially
revised the PIS and informed consent forms, which included improving the readability score
from 35 (academic level) to more than 70 (general population level). At enrolment, partici-
pants were randomly assigned (1:1) to receive daily Truvada either immediately or wait-listed
to receive Truvada after a deferred period of one year. Regular sexual partners were encour-
aged to enrol together and both partners allocated to the same group to minimise the possibil-
ity of drug sharing. The study design, baseline characteristics of the cohort and results have
been presented elsewhere [27, 28].
After enrolment, participants were asked to attend the clinic quarterly for HIV and STI
screening, with an extra visit one month after starting PrEP to check safety and tolerability (at
month 1 for the immediate group and month 13 for the deferred group). Notifications of HIV
sero-conversion for participants who did not return for follow-up visits were sourced from
electronic clinic records in other PROUD clinics and Public Health England (PHE) database.
Participants were asked to self-complete a baseline questionnaire providing demographic data
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at enrolment (on paper), monthly sexual behaviour and adherence questionnaires (on paper
or online), daily sexual behaviour and adherence diaries (on paper or online), and an accept-
ability questionnaire at the 12 month follow-up visit (on paper). The acceptability question-
naire was developed by the social science advisory group and is available as supporting
information file S1 Questionnaire. Paper questionnaires were placed in an envelope, sealed
and posted to the central data management team for data entry in MACRO database.
We used the Pearson chi-squared test, or the Fisher exact test where numbers were five or
less in any group, to compare responses to the acceptability questions based on trial arm allo-
cation (immediate or deferred), age group (34 and below or 35 and above, split at the median
age of the cohort), educational level (degree or below), ethnicity (white/Irish or Black, Asian
and minority ethnicity [BAME]), clinic of enrolment (inside or outside London), employment
status (full/part-time employed or not) and place of birth (UK or not). Quantitative data were
analysed using Stata 14.
In addition to categorical questions about acceptability, we asked participants to write what
they most and least liked about the study and coded the free-text responses in Excel using
emergent themes. The first author coded the free-text and two co-authors (EB, WN) checked
the coding for consistency.
From February 2014 to January 2015, we purposely sampled 25 study participants to take
part in semi-structured in-depth interviews (IDIs) which included a discussion topic on study
acceptability. Participants were selected based on trial arm allocation (immediate or deferred),
changes in their self-reported risk behaviour since enrolment (increased risk or same/decreased
risk), and PrEP adherence among participants in the immediate group (high or low). We aimed
to interview an equal number of participants in each of the six groups. During the interviews,
we asked participants about the acceptability of the study design and procedures. Researchers
who were independent of the study clinic team conducted the IDIs. Participants provided writ-
ten informed consent and the IDIs were conducted in English and were audio-recorded. The
recordings were transcribed, coded and analysed using framework analysis in NVivo 10 [30].
The PROUD study protocol was approved by London Bridge Research Ethics Committee,
the Medicines and Healthcare products Regulatory Agency and each of the 12 participating
Hospital Trusts (see list in acknowledgments). The trial is registered with ISRCTN (number
ISRCTN94465371) and ClinicalTrials.gov (NCT02065986). The study protocol, including par-
ticipant information sheet (PIS) and informed consent form (ICF), and the in-depth interview
PIS, ICF and interview guide, are available on the study website.
Results
In order to contextualise the acceptability of the study design, we present this in the context
of the overall acceptability of the study. As such, we present the characteristics of the study
cohort, acceptability of the study design, acceptability of the study visits, and acceptability of
the study procedures. Within each section we present the quantitative data from the accept-
ability questionnaire, the free text responses from the acceptability questionnaire which are
presented as proportions of responses not participants, and qualitative data from the in-depth
interviews. To reduce the size of the tables, we make the data by employment status and date
of birth available in supporting information file S1 Table as we observed no statistically signifi-
cant differences in these analyses.
Characteristics of the study cohort
Quantitative data. Of 544 (immediate [I] = 275, deferred [D] = 269) participants enrolled,
415 (76%) completed an acceptability questionnaire. One hundred and twenty nine participants
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(I = 50, D = 79) did not complete a questionnaire. Of these 21 (I = 5, D = 16) did not return to
the PROUD study clinic after randomisation, 60 (I = 25, D = 35) did not have a visit at or after
the scheduled 12 month visit, and 48 (I = 20, D = 28) had a visit at or after the scheduled 12
month visit but did not complete the questionnaire.
A higher proportion of participants in the immediate (82%) compared to deferred (71%)
randomisation groups completed the acceptability questionnaire (p = 0.002) (Table 1). Par-
ticipants who completed the acceptability questionnaire were older than participants who
did not, at a median age of 36 (IQR 30–43) compared to 32 (IQR 28–40, p = 0.002). When con-
trolling for age, participants in the immediate group were almost twice as likely to have com-
pleted the questionnaire than participants in the deferred group (AOR: 1.86, 95% CI 1.24, 2.81,
p = 0.003). There was no evidence of differences between participants who completed the
questionnaire based on education level, ethnicity, clinic of enrolment (Table 1), employment
status or place of birth (available as supporting information file S1 Table).
The median time from enrolment to completion of the acceptability questionnaire was
12.13 months (IQR 11.80, 12.80). Of 190 participants in the deferred group who completed the
acceptability questionnaire, 125 completed it when first prescribed PrEP but before PrEP initi-
ation, 45 after starting PrEP, 11 before starting, and seven completed it but never started PrEP
(missing date of completion for two participants).
Free text data. Of the 415 (I = 225, D = 190) participants who completed the acceptability
questionnaire, 369 (I = 204, D = 165) reported 589 (I = 323, D = 266) free text items that they
most liked about the study. Forty-one percent (239/589) of the items reported related to the
benefits of PrEP and HIV prevention more broadly, this equates to 45% (146/323) of all issues
Table 1. Comparison of participants who complete an acceptability questionnaire to those who didn’t.
Completed Questionnaire
All (col %) Yes (row %) P-value
544 (100%) 415 (76%)
Trial arm 0.002
Immediate 275 (51%) 225 (82%)
Deferred 269 (49%) 190 (71%)
Age 0.002
<25 54 (10%) 33 (61%)
25–34 210 (39%) 152 (72%)
35–44 178 (33%) 145 (81%)
>45 98 (18%) 83 (85%)
Education 0.178
Less than degree 213 (39%) 156 (73%)
Degree 327 (61%) 256 (78%)
Employed 0.369
No 100 (19%) 73 (73%)
Yes 439 (81%) 339 (77%)
UK Born 0.517
No 217 (40%) 169 (78%)
Yes 322 (60%) 243 (75%)
Ethnicity 0.524
BAME 100 (19%) 74 (74%)
White/Irish 439 (81%) 338 (77%)
Clinic 0.886
In London 381 (70%) 290 (76%)
Out of London 163 (30%) 125 (77%)
https://doi.org/10.1371/journal.pone.0175596.t001
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raised by the immediate group and 35% (93/266) of all issues raised by participants in the
deferred group. Fifty-nine percent (350/589) of the items reported related to study acceptabil-
ity. The key points raised about the acceptability of the study are presented in order of report-
ing in Table 2 and are discussed below. Prioritisation of issues hardly differed between
participants in the immediate and deferred groups, and the narratives within the issues were
very similar.
Of the 415 participants who completed the questionnaire, 315 (I = 179, D = 136) provided
360 (I = 199, D = 161) responses when asked what they least liked about the study. Fourteen
percent (51/360) of the items reported related to the use of PrEP (I = 32, D = 19). Eighty six
percent (309/360) of the items reported related to study acceptability and are presented in
Table 3 and discussed below. In this analysis, 25% of participant responses reported there was
nothing they disliked about the study, which was almost twice as high in the immediate group
(32%) compared to the deferred group (17%).
Qualitative data. We conducted 25 IDIs with 11 participants in the immediate and 14 in
the deferred group. Categorisation based on the risk and adherence matrix used for purposeful
sampling is shown in the figure in S1 Fig. The participants were enrolled across seven clinics,
two of which were outside of London. Participants were a median age of 37 (range 25 to 55
years), 23 were in employment and 16 were educated to degree level. Twenty-four male (23
gay and one bisexual) and one trans female participated in IDIs. At the time of interview, par-
ticipants had been enrolled in the study for a median of 12 months (range five to 20 months).
Acceptability of study design
Quantitative data. Overall, 97% of participants reported being ‘glad they joined the
study’, with only one person who was randomised to the immediate group disagreeing with
this statement (Table 4). The vast majority (96%) expected to remain enrolled for the duration
of the study. Eighty-seven percent were interested in joining another PrEP study after PROUD
if available, however this differed by trial arm with 92% in the immediate group and 81% in
the deferred group interested in joining another PrEP study (p = 0.002). Despite these high lev-
els of study acceptability, 74% thought that the chance of being in the deferred group might
put other volunteers off joining the study.
The majority agreed that the participant information sheet clearly explained the study
(98%), although this differed by educational level with 10 participants educated to degree level
stating the information sheet did not clearly explain the study or being neutral on this point,
compared to none with less than degree level education (p = 0.021). There are no additional
data to indicate why they did not think the information sheet was clear. There were no other
significant differences based on other demographic factors.
Table 2. What participants most liked about the study.
All Immediate Deferred
Contributing to research 110 31% 61 34% 49 28%
Study staff 97 28% 48 27% 49 28%
HIV/STI testing 71 20% 30 17% 41 24%
Easy to participate 20 6% 13 7% 7 4%
Access to support/referrals 21 6% 8 5% 13 8%
Information 18 5% 11 6% 7 4%
Recording sexual behaviour 11 3% 6 3% 5 3%
All/no comment 2 1% 0 0% 2 1%
TOTAL 350 177 173
https://doi.org/10.1371/journal.pone.0175596.t002
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Free text data. In the free text data, 31% (110/350) of participant responses noted that
being able to contribute to HIV prevention research was what they most liked about participat-
ing in the study, as this quote illustrates:
“It feels like I’m helping the gay community to fight and eradicate HIV” (deferred).
While no one in the immediate group cited the wait-listed design when asked what they
liked least about the study, 20% (27/136) of participants in the deferred group noted ‘being
deferred’ as the thing they liked least. This was the second most common reported item dis-
liked after the data collection tools, even though it only accounted for 19% (27/142) of all least
liked issues raised by deferred participants:
“I was slightly disappointed to be put in the deferred treatment group but understand the
necessity of this” (deferred).
“Having to wait a year to start PrEP during the highest risk period of my life” (deferred).
Qualitative data. Participants in the IDIs had a good understanding of the rationale for
the open-label wait-listed study design in terms of assessing effectiveness, adherence, changes
in risk behaviour, acquisition of other STIs, and the cost-effectiveness of an NHS funded PrEP
programme.
Seventeen participants (I = 6, D = 11) discussed the acceptability of the wait-listed study
design in some detail when asked about it. Most accepted the design with participants in the
immediate group stating they would have been disappointed to be randomised to the deferred
group but would have accepted it. Similarly, participants in the deferred group stated they
were disappointed to be randomised to the deferred group but accepted it. The general sense
was that volunteers knew what they were signing up to:
“I was slightly disappointed because I knew I was at risk by my behaviour at the time, I was
hoping to get on it (PrEP) for the full 2 years, but obviously it was always made clear right
Table 3. What participants least liked about the study.
All Immediate Deferred
Nothing 78 25% 54 32% 24 17%
Data
Paper questionnaires 45 15% 26 16% 19 13%
diary 37 12% 21 13% 16 11%
data 27 9% 11 7% 16 11%
online 23 7% 15 9% 8 6%
Study
visits 34 11% 18 11% 16 11%
deferred 27 9% 0 0% 27 19%
tests 22 7% 12 7% 10 7%
procedures 6 2% 3 2% 3 2%
feedback 5 2% 3 2% 2 1%
staff 2 1% 1 1% 1 1%
support 2 1% 2 1% 0 0%
recording 1 0% 1 1% 0 0%
TOTAL 309 167 142
https://doi.org/10.1371/journal.pone.0175596.t003
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from the start that there was a deferred group and there was an immediate group, so I
couldnt complain. It soon came around anyway and it was in time, so (laughter)” (deferred
participant who started PrEP before the IDI).
The issue raised in this quote about hoping to access PrEP ‘in time’ before contracting HIV
emerged in a hand-full of interviews with deferred participants:
“If I get infected in the first year I would be pretty angry I think. . .. we know that this exists
and we don’t (have it), so why not. . . I can almost predict that I will run into something
(test positive) at the last test. . .. then I will be quite upset”.
A participant who sero-converted during the deferred period described his experience as
follows:
“Knowing how effective Truvada is I think everyone would rather be in the immediate
rather than the control, because obviously your chances are better, but it is a 50/50 chance a
roll of the dice, I wasn’t particularly put off or anything by being in the deferred”.
Only one participant, who had used PrEP before joining the study, said he had not
understood there was a chance of being deferred until he was deferred, but accepted the
randomisation:
“The 12 months actually gave me a chance to think about it (PrEP) again, rather than just
taking a tablet, but actually do I need it, do I want it. So actually I reassessed my situation,
whether I should use PrEP or not use PrEP and how I sexually behave whilst using PrEP or
not using PrEP”.
Only five (I = 1, D = 4) participants specifically objected to the wait-listed design. A partici-
pant in the immediate group said he probably would not have returned to the clinic if he had
been randomised to the deferred group. A participant in the deferred group described how he
had planned to accept being randomised to either group, but after spending many hours in the
clinic due to delays, was “incandescent with rage” when finally randomised to the deferred group.
Instead of returning to the clinic, he enrolled a second time at a different clinic and was rando-
mised to the immediate group (he was one of two co-enrolments excluded from the final analy-
ses). The other three deferred participants were not convinced of the need for the deferred group
describing it as a ‘wasted year’ and ‘unfair’. In addition, two other participants interviewed,
reported use of PrEP accessed outside of the trial during their deferred period in the trial.
Acceptability of study visits
Quantitative data. The majority of participants didn’t mind visiting the clinics quarterly
(89%), liked having regular HIV (93%) and STI (87%) screening, and felt there were able
to access as much support as they needed to reduce the risk of HIV and other STIs (90%)
(Table 5). However, 8% of older participants compared to only 4% of younger participants did
not like regular STI screening (p = 0.027). Although a similar proportion of BAME and white
participants felt that they were able to access as much support as they needed to reduce their
risk behaviour (92% v 90%), there were differences in their reporting of a neutral (4% v 10%)
or negative response (4% v 1%), (p = 0.029). However, these differences are difficult to inter-
pret with such small numbers and differential representation of BAME participants across
clinics.
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Pharmacokinetic samples were collected from 59 participants, but all participants were
asked about the hypothetical acceptability of drug level monitoring to assess adherence in a
future trial. In a series of three questions, 96% of participants thought that drug level monitor-
ing was a good idea, 86% reported they would like to know their drug levels when on PrEP,
and only 16% felt that there was no need to conduct drug level testing to assess adherence.
These perspectives did not differ by trial allocation or baseline demographics.
Free text data. In the free text data, a fifth (20%) of participant responses related to the
benefits of regular HIV and STI testing in terms of helping them manage their sexual health
by providing a structure for regular testing. Twenty-eight percent of participant responses
reported the service they received from the study staff as the aspect of the study they most
liked. The following descriptors were used in relation to the staff (in alphabetical order):
‘Accessible, amazing, approachable, caring, courteous, efficient, friendly, great, helpful,
honest, having integrity, incredible, informative, kind, non-judgement, openly talk about
sex, patient, pleasant, polite, professional, reassuring, supportive, trustworthy and
understanding’.
Participants particularly appreciated the consistency of care by being able to see the same
health professionals regularly and build a relationship with the clinical team, as shown in this
response:
I most liked.. “the offer of seeing one designated person every 3 months for a check-up
rather than being passed from person to person in a clinic” (deferred)
Other points that participants most liked included the ease of attending study visits and
adhering to study procedures (6%), access to support and referral systems (6%), access to addi-
tional information about the study, study progress and HIV prevention more generally (5%).
Least liked aspects of the study visits included difficulties of getting appointments and travel
time to the clinics (11%), having blood taken and fear of needles (7%), specific procedures
(recruitment, enrolment, aims unclear, partner enrolment, recruitment closing) (2%), lack of
feedback in terms of an online forum or support phone line (2%), poor treatment by staff
(1%), and lack of support (1%).
Qualitative data. The qualitative data reinforces findings from the quantitative data
with the majority of participants reporting that they liked the regular clinic visits and HIV and
STI screening. However, three participants did comment on the “minor inconvenience” of
quarterly visits, and the difficulty of attending clinics especially during working hours. A few
participants would have preferred pre-booked quarterly appointments with visit reminders.
Another participant liked the convenience of being able to go to any clinic, not just the study
clinic, for HIV and STI screening. A participant in the deferred group had not attended the
clinic for six months and felt that, without the motivation of PrEP to attend, it was easy to lose
touch with the clinic. He thought that additional email contact with participants during the
deferred period would ensure better retention.
As in the free text findings, participants in the IDIs praised the clinic staff without being
prompted to talk about them, especially the fact that they were welcoming, respectful and non-
judgemental. They also highlighted the benefit of seeing the same staff members regularly in
the clinic, as this quote highlights:
“It is really important to me. . . I don’t know him very well, but I have been able to disclose
a few things to him. . . It means it is not caught up in my head, I am not denying it, I am not
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avoiding it, I am not parking it in the ether, and I wouldn’t be able to do that if it was a ran-
dom team member . . .even though I don’t know him very well the relational aspect is really
important”.
Acceptability of study data collection tools
Quantitative data. Acceptability of the data collection tools differed by individual tool
with 82% of participants reporting they didn’t mind completing the monthly sexual behaviour
questionnaires, 56% reporting they didn’t mind completing the daily sexual behaviour and
adherence diary, and 56% reporting liking completing the questionnaires online (Table 6). How-
ever, there was evidence of a difference by trial arm in the proportion of participants who agreed
(22% in immediate, 16% in deferred) or were neutral or uncertain (20% in immediate, 30% in
deferred) in response to the statement that they disliked completing the daily diary (p = 0.036).
Younger participants disliked the sexual behaviour diary more than older participants (23%
v 16%, p = 0.019) and older participants liked completing the questionnaires online more than
younger participants (62% v 48%, p = 0.007). Similarly, participants enrolled outside of Lon-
don liked completing the questionnaires online more than participants enrolled in London
(65% v 52%, p = 0.014).
Fifty-eight percent of participants reported they would have preferred to answer the sexual
behaviour questions on a mobile device (i.e. smart phone or tablet). This was in comparison to
being able to answer the questions on a paper questionnaire or via the on-line database. As
above, this differed by age with 73% of younger compared to only 47% of older participants
being interested in this option (p<0.001).
In terms of self-completed questionnaires, 88% felt they could report sexual activity hon-
estly, although 47% found it difficult to remember sexual activity over the last 30 days and 28%
thought the questionnaires made it difficult to accurately report sexual activity. This differed
by age with 54% of younger compared to 41% of older participants finding it difficult to
remember their sexual behaviour (p = 0.026).
Free text data. In the free text responses, the data collection tools were the most fre-
quently reported least liked aspect of the study by participants in both groups. A total of 132
participants (I = 73, D = 59) mentioned at least one data related item that they disliked: 15% of
responses related to the monthly self-completed questionnaires, 12% to the daily diary, 9% to
data collection generally, and 7% specifically about the online participant website where partic-
ipants could complete the questionnaires and diary.
Participants said that there were too many forms to complete with the monthly sexual
behaviour and adherence questionnaire and daily diary and that it was difficult to remember
to complete them. They described the questionnaires and diary as being cumbersome, fiddly, a
chore to complete and time consuming. In addition, the questionnaires were described as
being too long, frustrating, repetitive and unclear, and the diary as being awkward, laborious,
not user friendly, a pain, and tedious, as this quote demonstrates:
“The online diary site is SUCH a pain! Having to click into each day separately is very
laborious” (deferred, emphasis by participant).
Participant suggestions included having email reminders to complete the questionnaire
and diary, to have longer than the 2 week cut off point to complete the last months question-
naire, to be able to view the diary in order to complete the monthly questionnaire, and to be
able to block edit days in the diary, repeat data from the previous day or merely complete the
diary when you had missed a tablet or had sex.
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A number of participants complained that it was difficult to recall sexual behaviour when
completing the questionnaire and diary. A few also complained that they were not able to
report their behaviour as accurately as they would have liked as the questionnaire and diary
did not allow them to report behaviour that was not requested (i.e. group sex, ejaculation), or
to elaborate on reasons for specific behaviours, for example:
“Diary doesn’t cover all issues, what about non anal sex partners? More than 1 partner a
day? Other reasons for not taking pills other than forgot e.g. illness or travel” (immediate)
A number of participants described the online website as difficult to access, unreliable and
‘clunky’, with some arguing that they would have preferred a mobile application. One person
raised a concern about data protection issues with the online website.
While 1% of least liked responses related to recalling numbers of sexual partners, 3% of
most liked responses related to participants liking the need to recall and record their sexual
behaviour as it made them review their behaviour and consider changes:
“It made me feel more aware of my sexual health and has made me less likely to be unsafe
than one year ago” (immediate).
Qualitative data. In the qualitative interviews, there was almost an even split between
people who liked and didn’t like completing the questionnaires and diaries. Much of the nega-
tive feedback received in the free text responses was repeated in the IDIs including the fact that
the data collection tools were duplicative, questions were ambiguous, and the diaries were dif-
ficult to complete especially in terms of having to enter data about not having sex and not tak-
ing PrEP each day. In addition, participants reported that they rarely completed the diary
daily, more likely weekly or monthly either from memory or from personal diaries or even
spreadsheets.
As in the free text responses, some participants were frustrated that the questionnaire and
diary were restrictive, not allowing participants to add comments or explain entries. In the
IDIs, it was clear that this mainly related to participants wanting an opportunity to explain
their rationale for risk taking or actions that may be perceived by the categorical approach of
data collection to be more risky than the participant felt they actually were.
Out of 12 participants who talked about the accuracy of their self-reported data, half
thought they were very accurate and half didn’t, mainly due to forgetting to complete the diary
regularly, difficulty recalling their behaviour accurately, and difficulty being as accurate as they
wanted to be given the categorical nature of the data collection tools.
Recommendations on how to improve data collection included reminders for both visits
and data completion, completing the data on a mobile application, having questionnaires
administered instead of self-completed which one participant did not think would increase
social desirability bias, and more opportunities for participants to describe their behaviour
instead of ticking categorical options.
Discussion
This is the first study to assess the acceptability of using an open-label wait-listed design to
evaluate the effectiveness of a new biomedical HIV prevention technology. The first concern
when designing the trial was the possibility that randomisation to the deferred group would
discourage volunteers from enrolling. Although we enrolled to target, accrual was slower than
expected, partly due to limited PrEP awareness [28]. In this paper, we show that three-quarters
of participants thought the wait-listed design would discourage other volunteers from joining
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a similar study. This evidence suggests that the wait-listed design probably contributed to the
slower than anticipated rate of recruitment. This is an important consideration in planning
future wait-listed trials.
The second concern when designing the trial was that retention would be lower in the
deferred-group, potentially compromising the validity of the trial result. We reported previ-
ously that participants in the immediate-group attended clinic more regularly than deferred-
group participants to collect their PrEP prescriptions, with a mean of 4.2 compared to 3.6 visits
in the first year [29]. Without the facility to identify new HIV sero-conversions via the PHE
database, this could have affected the outcome of the trial. Indeed, a fifth of deferred partici-
pants reported the wait-listed design as an element they disliked about the study. Given com-
pletion of the acceptability questionnaire was significantly lower among participants in the
deferred than the immediate group, this is likely to underestimate the extent to which partici-
pants disliked the wait-listed design. However, it is interesting to note that in free-text data,
deferred participants disliked the data collection tools more than the fact that they had to wait
a year to access PrEP. In fact, overall, participants had more reservations about the data collec-
tion tools than any other aspect of the study design, visits or procedures. The quantitative and
qualitative findings suggest that in an environment where PrEP was not available, the rationale
for the wait-listed design was well understood and generally acceptable to most participants.
Our findings on the acceptability of study visits provide some lessons for PrEP implementa-
tion, as well as future prevention research. In England, MSM are advised to have HIV and STI
screening at least annually, and every 3 months if having condomless sex with new or casual
partners [31]. At enrolment, participants reported screening for STIs a median of 3 (IQR 2–4)
times in the previous 12-months [28] During the study, PROUD participants clearly found
that in the context of PrEP provision, quarterly clinic visits and the routine of regular HIV and
STI screening were acceptable. These findings suggest that among a cohort of MSM who are
engaged with sexual-health services and perceive themselves to be at risk of HIV, regular clinic
visits are likely to be acceptable in future PrEP programmes. However, we still know very little
about the optimal ways to deliver PrEP to individuals at risk of HIV who are less engaged with
sexual-health services or do not perceive their risk to be sufficient to access PrEP. Additionally,
in a sub-sample of the study population we used drug level testing to confirm participant’s
adherence to daily dosing. Among all participants, the idea of drug level testing was perceived
as an acceptable procedure. While this finding is useful for future clinical trials, this type of
adherence assessment is unlikely to be deemed necessary in a clinical setting in the UK.
Another lesson for implementation is the importance of seeing the same health profession-
als regularly in terms of building rapport with the staff. While participants felt they could
access as much support as they needed to reduce their risk of HIV and STIs, we did not mea-
sure the type of support they wanted in the context of PrEP use. In the baseline cohort, 9.5% of
participants reported moderate to severe depression and 44% reported the use of recreational
drugs commonly associated with chemsex [28, 32]. In planning a PrEP implementation pro-
gramme, we need to explore the types of support services that PrEP users require and the best
ways to offer these services.
PROUD was originally designed as a pilot study and as such, feedback on the shortcomings
of the data collection tools was valuable in preparation for a larger-scale RCT. We asked partic-
ipants to self-complete sexual-behaviour and adherence questionnaires to reduce the impact of
social desirability bias and reduce the clinic workload. Four-fifths of participants didn’t mind
completing the questionnaires and over half didn’t mind completing the daily-diary. This is
despite feedback that there were too many questionnaires, questions were often unclear, and
the online data entry site was difficult to use. This suggests that while participants were critical
of the data collection tools, the majority did not object to providing self-completed data and
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felt they were able to do so honestly. Of note, almost half of participants found it difficult to
recall their sexual activity in the last 30 days. The key lessons are that the data collection tools
need to be streamlined, for example by using clearer categorizations, cover shorter time-peri-
ods or be supported with aides-memoire, and available on multiple devices, including mobile
apps, to meet a variety of individual preferences.
Participants were critical about the design of the questionnaires with over a quarter stating
they made it difficult to accurately report sexual behaviour, an issue echoed in the free-text
responses. While there is a lot of room for improvement of the questionnaires, this issue also
relates to the challenge of collecting data on sexual risk behaviour in the current HIV land-
scape. We know from previous analysis that for participants in this study, it was clear that a
‘risk’ depended not only on condom use, but also PrEP use, a partners HIV-status and viral-
load, whether the participant was top or bottom, and whether ejaculate was involved [33]. In
the era of PrEP and treatment as prevention (TasP), we need to reconsider the questions we
use to measure risk behaviour, taking account of both the need to streamline the data collec-
tion tools and realistically capture ‘risk’ from the perspective of participants. As noted by other
authors, we need to adapt measures of risk to take account of the expanded HIV prevention
options which include the use of ARVs by both positive and negative individuals, and move
away from simplified notions of condomless sex being ‘unprotected’, ‘unsafe’ or a ‘risk’ factor
for HIV acquisition [34, 35].
Although we were specifically interested in assessing acceptability of the trial design, it was
useful to contextualise participant’s perceptions within the broader context of acceptability of
study procedures more generally. This analysis benefits from that fact that we assessed accept-
ability of the study across participants in the immediate and deferred groups. However, one
limitation is that a quarter of participants did not complete the acceptability questionnaire and
they were almost twice as likely to be in the deferred group. We attempted to arrange in-depth
interviews with participants who had stopped attending the clinic or withdrawn from the
study, but were either unable to contact them or they were unwilling to attend an in-depth
interview. Another limitation is that we relied on the self-completed sexual behaviour data to
purposely select participants for the in-depth interviews, and therefore did not sample partici-
pants who did not complete any questionnaires. A further limitation is that although trans
women were eligible to join the study, our recruitment strategy was not sufficiently trans inclu-
sive and therefore only three trans women joined the study. As such, these findings only really
reflect the views of the cis men who joined the study. Our findings highlight the benefit of
using mixed method research approaches to assess the acceptability of study designs, proce-
dures and data collection processes in preparation for large-scale clinical trials.
Our findings demonstrate that for PROUD, the open-label wait-listed RCT was an accept-
able and feasible trial design. It was the optimal design to estimate the net-effect of PrEP in
terms of biological efficacy, product adherence and risk compensation. It also enabled a com-
parison of behaviour change and rates of STIs between the groups, as well as HIV incidence.
Without the deferred control-group, the study results would have been uninterpretable as HIV
incidence in the intervention group was comparable to the expected HIV incidence among
MSM attending sexual health clinics and yet incidence in the control-group was seven-times
higher than expected [29]. The open-label wait-listed RCT design is not a panacea to the chal-
lenges that some placebo-controlled biomedical prevention trials have faced in terms of
achieving sufficient adherence. However, in this case, an open-label wait-listed RCT was the
optimal design to address the research question of interest in PROUD and provided the most
valid measure of public health benefit.
Given the challenges of achieving sufficient adherence in recent biomedical HIV prevention
trials, evidence from open-label wait-listed RCTs should be considered to support public
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health interventions, as in PROUD, as well as in support of licensing applications of new drugs
where appropriate. The World Health Organisation now recommends PrEP for populations
with an HIV incidence of three per 100 person-years, although access remains extremely lim-
ited in most countries [36]. Future biomedical HIV prevention trials will need to consider
including oral PrEP as either the control group or an additional standard of care. While there
may still be circumstances whereby the open-label wait-listed RCT remains ethically accept-
able for the evaluation of new biomedical HIV prevention technologies, this trial design should
be considered more broadly when the presence of a placebo could impede adherence suffi-
ciently to undermine the power of an RCT.
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